2023-06-300001648257--12-312023Q2false00016482572023-01-012023-06-300001648257us-gaap:CommonStockMember2023-01-012023-06-300001648257us-gaap:CommonStockMember2022-01-012022-06-300001648257us-gaap:RetainedEarningsMember2023-06-300001648257us-gaap:ParentMember2023-06-300001648257us-gaap:NoncontrollingInterestMember2023-06-300001648257us-gaap:AdditionalPaidInCapitalMember2023-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001648257us-gaap:RetainedEarningsMember2022-12-310001648257us-gaap:ParentMember2022-12-310001648257us-gaap:NoncontrollingInterestMember2022-12-310001648257us-gaap:AdditionalPaidInCapitalMember2022-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001648257us-gaap:RetainedEarningsMember2022-06-300001648257us-gaap:ParentMember2022-06-300001648257us-gaap:NoncontrollingInterestMember2022-06-300001648257us-gaap:AdditionalPaidInCapitalMember2022-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001648257us-gaap:RetainedEarningsMember2021-12-310001648257us-gaap:ParentMember2021-12-310001648257us-gaap:NoncontrollingInterestMember2021-12-310001648257us-gaap:AdditionalPaidInCapitalMember2021-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001648257hcm:HCMLShareOptionSchemeMember2021-01-012021-12-310001648257hcm:HCMLShareOptionSchemeMember2021-12-310001648257hcm:ExecutiveDirectorMemberhcm:HCMLShareOptionSchemeMemberdei:AdrMember2022-05-012022-05-310001648257hcm:ShareOptionScheme2005Member2023-06-300001648257hcm:HCMLShareOptionSchemeMember2022-01-012022-12-310001648257hcm:HCMLShareOptionSchemeMember2022-12-310001648257srt:MinimumMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257srt:MaximumMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257hcm:ShareOptionScheme2005Member2005-06-042005-06-040001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2023-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2022-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-12-310001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257hcm:ExecutiveDirectorMemberhcm:HCMLShareOptionSchemeMember2022-05-012022-05-310001648257us-gaap:OtherNoncurrentLiabilitiesMember2023-06-300001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2023-06-300001648257us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2022-12-310001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationLicensingRevenueMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2023-01-012023-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationLicensingRevenueMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257hcm:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:ServicesCollaborationResearchAndDevelopmentFromDeferredUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:ServicesCollaborationResearchAndDevelopmentFromCostReimbursementsMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:OtherCollaborationLicensingRevenueMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:LicensingFromUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:ThirdPartiesMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMember2023-01-012023-06-300001648257hcm:RelatedPartiesMember2023-01-012023-06-300001648257hcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2023-01-012023-06-300001648257hcm:OtherCollaborationLicensingRevenueMember2023-01-012023-06-300001648257hcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:MarketedProductsMember2023-01-012023-06-300001648257hcm:GoodsDistributionMember2023-01-012023-06-300001648257hcm:CommercializationServicesMember2023-01-012023-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2023-01-012023-06-300001648257hcm:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001648257hcm:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationLicensingRevenueMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMember2022-01-012022-06-300001648257hcm:ResearchAndDevelopmentServicesMember2022-01-012022-06-300001648257hcm:RelatedPartiesMember2022-01-012022-06-300001648257hcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2022-01-012022-06-300001648257hcm:OtherCollaborationLicensingRevenueMember2022-01-012022-06-300001648257hcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:MarketedProductsMember2022-01-012022-06-300001648257hcm:GoodsDistributionMember2022-01-012022-06-300001648257hcm:CommercializationServicesMember2022-01-012022-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2022-01-012022-06-300001648257hcm:CollaborativeArrangementsMember2023-01-012023-06-300001648257hcm:CollaborativeArrangementsMember2022-01-012022-06-300001648257us-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257us-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257us-gaap:RetainedEarningsMember2022-01-012022-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:CapitalAdditionsMember2023-01-012023-06-300001648257us-gaap:CapitalAdditionsMember2023-01-012023-06-300001648257us-gaap:RevolvingCreditFacilityMember2022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2021-10-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2022-01-012022-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2022-12-310001648257hcm:HCMLShareOptionSchemeMember2023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:CorporateAndReconcilingItemsMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:CorporateAndReconcilingItemsMember2022-01-012022-06-300001648257hcm:LongTermIncentivePlanMember2023-06-300001648257hcm:LongTermIncentivePlanMember2022-12-310001648257us-gaap:RevolvingCreditFacilityMember2022-05-012022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2021-10-012021-10-310001648257us-gaap:RevolvingCreditFacilityMemberhcm:HongKongInterbankOfferedRateMember2022-05-012022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMemberus-gaap:PrimeRateMember2021-10-012021-10-310001648257hcm:UnitedStatesAndOthersMember2023-01-012023-06-300001648257country:HK2023-01-012023-06-300001648257country:CN2023-01-012023-06-300001648257hcm:UnitedStatesAndOthersMember2022-01-012022-06-300001648257country:HK2022-01-012022-06-300001648257country:CN2022-01-012022-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberhcm:CommercializationServicesMember2023-01-012023-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2023-01-012023-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:CommercializationServicesMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2022-01-012022-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2022-01-012022-06-300001648257hcm:OtherVenturesSegmentMember2023-06-300001648257hcm:OncologyOrImmunologySegmentMember2023-06-300001648257hcm:OtherVenturesSegmentMember2022-12-310001648257hcm:OncologyOrImmunologySegmentMember2022-12-3100016482572023-01-010001648257us-gaap:CommonStockMember2023-06-300001648257us-gaap:CommonStockMember2022-12-310001648257us-gaap:CommonStockMember2022-06-300001648257us-gaap:CommonStockMember2021-12-310001648257hcm:OtherCurrencyMember2023-06-300001648257currency:USD2023-06-300001648257currency:HKD2023-06-300001648257currency:GBP2023-06-300001648257currency:CNY2023-06-300001648257hcm:OtherCurrencyMember2022-12-310001648257currency:USD2022-12-310001648257currency:HKD2022-12-310001648257currency:GBP2022-12-310001648257currency:CNY2022-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2023-06-300001648257hcm:CorporateAndReconcilingItemsMember2023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2022-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2022-12-310001648257hcm:CorporateAndReconcilingItemsMember2022-12-3100016482572022-06-3000016482572021-12-310001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257hcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:NoncontrollingInterestMember2023-01-012023-06-300001648257us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001648257hcm:NotLaterThanThreeMonthsMember2023-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2023-06-300001648257hcm:LaterThanOneYearMember2023-06-300001648257hcm:BetweenThreeMonthsToSixMonthsMember2023-06-300001648257hcm:BetweenSixMonthsToOneYearMember2023-06-300001648257hcm:NotLaterThanThreeMonthsMember2022-12-310001648257hcm:NonControllingShareholdersOfSubsidiariesMember2022-12-310001648257hcm:LaterThanOneYearMember2022-12-310001648257hcm:BetweenThreeMonthsToSixMonthsMember2022-12-310001648257hcm:BetweenSixMonthsToOneYearMember2022-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-01-012022-06-300001648257us-gaap:RetainedEarningsMember2023-01-012023-06-300001648257us-gaap:ParentMember2022-01-012022-06-300001648257us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001648257srt:MinimumMember2023-01-012023-06-300001648257srt:MaximumMember2023-01-012023-06-300001648257srt:MinimumMember2022-01-012022-12-310001648257srt:MaximumMember2022-01-012022-12-310001648257hcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257hcm:VestingBasedOnNonPerformanceMemberhcm:GrantDateSeptember132022TwoMemberhcm:LongTermIncentivePlanMember2022-09-132022-09-130001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2023-06-300001648257hcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateJune052023Memberhcm:LongTermIncentivePlanMember2023-06-052023-06-050001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateSeptember132022OneMemberhcm:LongTermIncentivePlanMember2022-09-132022-09-130001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateMay232022Memberhcm:LongTermIncentivePlanMember2022-05-232022-05-230001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateJune052023Memberhcm:LongTermIncentivePlanMember2023-06-050001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateSeptember132022OneMemberhcm:LongTermIncentivePlanMember2022-09-130001648257hcm:VestingBasedOnNonPerformanceMemberhcm:GrantDateSeptember132022TwoMemberhcm:LongTermIncentivePlanMember2022-09-130001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateMay232022Memberhcm:LongTermIncentivePlanMember2022-05-230001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2022-01-012022-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257hcm:LongTermIncentivePlanMember2023-01-012023-06-3000016482572022-01-012022-12-310001648257us-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2021-01-012021-12-310001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-232023-01-230001648257us-gaap:SubsidiaryOfCommonParentMember2023-06-300001648257us-gaap:EquityMethodInvesteeMember2023-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2022-12-310001648257us-gaap:EquityMethodInvesteeMember2022-12-3100016482572022-06-2700016482572021-10-212021-12-310001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-230001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2022-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-01-012023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-01-012022-12-310001648257hcm:DueFromRelatedPartiesNoncurrentMember2023-06-300001648257hcm:DueFromRelatedPartiesCurrentMember2023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-01-012023-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2023-01-012023-06-300001648257us-gaap:ParentMember2023-01-012023-06-300001648257us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2023-06-300001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2022-12-3100016482572022-01-012022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-01-312023-01-310001648257hcm:SeroquelMember2023-06-3000016482572023-06-3000016482572022-12-31iso4217:USDiso4217:CNYxbrli:purehcm:areaxbrli:sharesiso4217:USDxbrli:sharesiso4217:HKDhcm:claim

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2023

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ Form 40-F ☐

​

​

​

​

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

​

​

​

​

Exhibit No.

    

Description

Exhibit 99.1

​

Announcement relating to unaudited financial results as of and for the six months ended June 30, 2023

Exhibit 99.2

​

HUTCHMED (China) Limited supplemental disclosures

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ JOHNNY CHENG

​

​

Name:

Johnny Cheng

​

​

Title:

Chief Financial Officer

​

Date: July 31, 2023

​

​